Hardman & Co partnered with London South East to host a Life Sciences Investor Briefing.
We were joined on the evening of 11 September by the CEO of Destiny Pharma, CEO of Open Orphan, the CFO of Hardman & Co client Shield Therapeutics, all AIM-listed companies.
The evening began by an interesting and informative talk from Dr Martin Hall who heads the Hardman Life Sciences team to put the sector in context. This was followed by presentations on three distinct investment opportunities.
This webcast is an ‘as-live’ record of the event and includes the Q&A after each presentation.
Our speakers were:
1. Dr Martin Hall, Head of Life Sciences, Hardman & Co 6:51
2. Neil Clark, CEO, Destiny Pharma 36:32
3. Tim Watts, CFO, Shield Therapeutics 1:01:16
4. Cathal Friel, CEO, Open Orphan 01:29:42